These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 19187170

  • 41. [Differences between diabetes mellitus type 2 patients switched and not switched over to insulin treatment after specialist consultation].
    Goddijn PP, Meyboom-de Jong B, Feskens EJ, van Ballegooie E, Bilo HJ.
    Ned Tijdschr Geneeskd; 1998 May 02; 142(18):1023-6. PubMed ID: 9623204
    [Abstract] [Full Text] [Related]

  • 42. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 02; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone.
    Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA.
    Diabet Med; 2007 Jul 02; 24(7):778-83. PubMed ID: 17535290
    [Abstract] [Full Text] [Related]

  • 45. The IMPROVE study--a multinational, observational study in type 2 diabetes: data from the Polish cohort.
    Gumprecht J, Zurawska G, Wolnik B, Dzida G.
    Endokrynol Pol; 2008 Jul 02; 59(6):460-6. PubMed ID: 19347809
    [Abstract] [Full Text] [Related]

  • 46. The IMPROVE study--a multinational, multicentre, observational study in type 2 diabetes: results from the Italian cohort.
    Giorda C, Boemi M, Borzì V, Chiaramonte F, Mattei P, Tribulato A.
    Acta Biomed; 2010 Sep 02; 81(2):115-24. PubMed ID: 21305876
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart.
    Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J.
    Scand J Clin Lab Invest; 2008 Sep 02; 68(8):739-44. PubMed ID: 19016075
    [Abstract] [Full Text] [Related]

  • 51. Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan.
    Ishii H, Iwase M, Seino H, Shuto Y, Atsumi Y.
    Curr Med Res Opin; 2011 Mar 02; 27(3):643-50. PubMed ID: 21250861
    [Abstract] [Full Text] [Related]

  • 52. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
    Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H.
    J Indian Med Assoc; 2011 Apr 02; 109(4):275-8. PubMed ID: 22187803
    [Abstract] [Full Text] [Related]

  • 53. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C, Shimizu T, Arakawa M, Mita T, Fujitani Y, Watada H, Kawamori R, Hirose T.
    Diabetes Res Clin Pract; 2009 Oct 02; 86(1):31-6. PubMed ID: 19692134
    [Abstract] [Full Text] [Related]

  • 54. Inhaled insulin delivery--where are we now?
    Muchmore DB, Gates JR.
    Diabetes Obes Metab; 2006 Nov 02; 8(6):634-42. PubMed ID: 17026487
    [Abstract] [Full Text] [Related]

  • 55. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet AY.
    Diabetes Res Clin Pract; 2013 Aug 02; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [Abstract] [Full Text] [Related]

  • 56. Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus.
    Braun A, Sämann A, Kubiak T, Zieschang T, Kloos C, Müller UA, Oster P, Wolf G, Schiel R.
    Patient Educ Couns; 2008 Oct 02; 73(1):50-9. PubMed ID: 18583087
    [Abstract] [Full Text] [Related]

  • 57. [Hypertension and insulin treatment in type 2 diabetes].
    Ben Salem Hachmi L, Bouguerra R, Maatki O, Smadhi H, Turki Z, Hraoui S, Ben Slama C.
    Arch Mal Coeur Vaiss; 2007 Aug 02; 100(8):664-7. PubMed ID: 17928772
    [Abstract] [Full Text] [Related]

  • 58. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes.
    Shah S, Das AK, Kumar A, Unnikrishnan AG, Kalra S, Baruah MP, Ganapathi B, Sahay RK.
    Adv Ther; 2009 Mar 02; 26(3):325-35. PubMed ID: 19252828
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug 02; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.